Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17303077rdf:typepubmed:Citationlld:pubmed
pubmed-article:17303077lifeskim:mentionsumls-concept:C0011860lld:lifeskim
pubmed-article:17303077lifeskim:mentionsumls-concept:C0229671lld:lifeskim
pubmed-article:17303077lifeskim:mentionsumls-concept:C0155765lld:lifeskim
pubmed-article:17303077lifeskim:mentionsumls-concept:C0963992lld:lifeskim
pubmed-article:17303077lifeskim:mentionsumls-concept:C0439793lld:lifeskim
pubmed-article:17303077lifeskim:mentionsumls-concept:C0332281lld:lifeskim
pubmed-article:17303077pubmed:issue2lld:pubmed
pubmed-article:17303077pubmed:dateCreated2007-2-27lld:pubmed
pubmed-article:17303077pubmed:abstractTextResistin, secreted from adipocytes, causes insulin resistance and diabetes in rodents. To determine the relation between serum resistin and diabetic microangiopathies in humans, we analyzed 238 Japanese T2DM subjects. Mean serum resistin was higher in subjects with either advanced retinopathy (preproliferative or proliferative) (P=0.0130), advanced nephropathy (stage III or IV) (P=0.0151), or neuropathy (P=0.0013). Simple regression analysis showed that serum resistin was positively correlated with retinopathy stage (P=0.0212), nephropathy stage (P=0.0052), and neuropathy (P=0.0013). Multiple regression analysis adjusted for age, gender, and BMI, revealed that serum resistin was correlated with retinopathy stage (P=0.0144), nephropathy stage (P=0.0111), and neuropathy (P=0.0053). Serum resistin was positively correlated with the number of advanced microangiopathies, independent of age, gender, BMI, and either the duration of T2DM (P=0.0318) or serum creatinine (P=0.0092). Therefore, serum resistin was positively correlated with the severity of microangiopathies in T2DM.lld:pubmed
pubmed-article:17303077pubmed:languageenglld:pubmed
pubmed-article:17303077pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17303077pubmed:citationSubsetIMlld:pubmed
pubmed-article:17303077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17303077pubmed:statusMEDLINElld:pubmed
pubmed-article:17303077pubmed:monthAprlld:pubmed
pubmed-article:17303077pubmed:issn0006-291Xlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:NishidaWataru...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:TakataYasunor...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:OsawaHaruhiko...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:OnumaHiroshiHlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:OchiMasaakiMlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:KatoKenichiKlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:ShimizuIkkiIlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:FujiiYasuhisa...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:OhashiJunJlld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:MakinoHideich...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:KawamuraRyoic...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:YamauchiJunko...lld:pubmed
pubmed-article:17303077pubmed:authorpubmed-author:TakasukaTomom...lld:pubmed
pubmed-article:17303077pubmed:issnTypePrintlld:pubmed
pubmed-article:17303077pubmed:day6lld:pubmed
pubmed-article:17303077pubmed:volume355lld:pubmed
pubmed-article:17303077pubmed:ownerNLMlld:pubmed
pubmed-article:17303077pubmed:authorsCompleteYlld:pubmed
pubmed-article:17303077pubmed:pagination342-6lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:meshHeadingpubmed-meshheading:17303077...lld:pubmed
pubmed-article:17303077pubmed:year2007lld:pubmed
pubmed-article:17303077pubmed:articleTitleSerum resistin is associated with the severity of microangiopathies in type 2 diabetes.lld:pubmed
pubmed-article:17303077pubmed:affiliationDepartment of Molecular and Genetic Medicine, Ehime, University Graduate School of Medicine, Toon, Ehime 791-0295, Japan. harosawa@m.ehime-u.ac.jplld:pubmed
pubmed-article:17303077pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17303077pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed